Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Regulatory News:

Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that three abstracts related to the company’s autologous NKG2D-based CAR-T candidates for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS) have been accepted for presentation at the 61^st American Society of Hematology (ASH) Annual Meeting, which will be held from December 7-10, 2019, in Orlando, Florida. In addition, management will host a live event at ASH for analysts and investors on Monday, December 9, to review the data from the three posters, as well as updates to the company’s development program for r/r AML and MDS and proprietary OptimAb manufacturing process.

Filippo Petti, chief executive officer of Celyad, noted, “We look forward to providing an update at next month’s ASH Annual Meeting on our autologous CAR-T program focused on the treatment of acute myeloid leukemia and myelodysplastic syndromes, including the latest clinical results from the CYAD-01 Phase 1 THINK and DEPLETHINK trials. In addition, we are excited to highlight the latest preclinical data from our next-generation NKG2D-based candidate CYAD-02 and our OptimAb manufacturing process, which underpins both autologous CAR-T assets within the program.”

ASH Investor/Analyst Event and Webcast Information
Celyad will host an event at ASH for investors and analysts on Monday, December 9, 2019, beginning at 8:30 p.m. ET to review data presented, as well as to provide updates on the company’s development program for r/r AML and MDS and its proprietary OptimAb manufacturing process. The event will also be webcast live and can be accessed under Events & Webcasts in the Investors section of the company’s website.

Poster Presentation Details:
The following abstracts published today are now available on the ASH website. Following presentation at the meeting, the posters will be available in the library section of Celyad’s website.

Publication #3826: Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells as Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Date & Time: Monday, December 9, 2019, 6 p.m. – 8 p.m. ET

Publication #3844: Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients